Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New laser blood test aims to detect breast cancer earlier

NCT ID NCT04273542

Diagnosis Sponsor: Centre Jean Perrin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This large study is testing whether a new laser-based blood test can help screen for breast cancer. Researchers will compare blood samples from women with and without breast cancer to see if the test can accurately spot the disease. If it works, it could offer a less invasive way to screen for breast cancer alongside mammograms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liquid biopsy (blood sample)
What this could lead to
If successful, this could lead to a simple blood test that helps detect breast cancer earlier, potentially reducing the need for some mammograms.
What could go wrong
This is a validation study, not a treatment trial. The new laser technique is still experimental and may not prove accurate enough to replace current screening methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2021

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \*For all participants : * Adult woman capable of giving informed consent to research participation * Affiliation to the French social security system \>For Control cohort: * Woman participating in organised screening or benefiting from individual follow-up, eligible as such for a mammogram \>For Patient cohort: * woman with invasive breast cancer T0N1, T1N0-1, T2N0-1 (histologically proven) at inclusion and before any cancer treatment \>For Exploratory cohort: * woman carrying the BRCA1/2 mutation, followed according to standard recommendations or * woman carrying the BRCA1/2 mutation suffering from in situ BC discovered on biopsy and histologically confirmed Exclusion Criteria: * For all participants : * Refusal to participate * Reluctant or unable to comply with study requirements * Pregnant or breastfeeding woman * History of breast cancer * For Patient cohort \- Patients with Stage III/IV or Bilateral Breast Cancer * For Control cohort: * Invasive breast cancer suspected at mammography before liquid biopsy\* * Mammography classified ACR3 or ACR4 * For Exploratory cohort: * Concomitant breast cancer * At inclusion visit, woman for whom an invasive breast cancer will be suspected at mammography will be include in Patient cohort after an histological proof of cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition breast carcinoma in situ breast neoplasm female breast carcinoma invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 mutation BRCA2 mutation Breast cancer female

Contacts and locations

Locations

  • Centre Eugène MARQUIS

    Rennes, France

  • Centre Jean PERRIN

    Clermont-Ferrand, Puy de Dome, 63011, France

  • Hôpital La Pitié Salpêtrière

    Paris, Île-de-France Region, 75000, France

  • Hôpital Saint-Louis

    Paris, Île-de-France Region, 75010, France

  • Hôpital Tenon

    Paris, Île-de-France Region, 75020, France

  • Institut de Cancérologie de l'Ouest

    Angers, France

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, France

  • La Chataigneraie (Selimed 63)

    Beaumont, Puy de Dôme, 63110, France

  • Pôle Santé République

    Clermont-Ferrand, Puy de Dôme, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.